The loss of FOXO1 and PDX1 transcription factor signaling in pancreatic β-cells, which results in the loss of insulin production prevalent in pathological conditions such as insulin resistance and T2DM, has been broadly demonstrated and identified as a key clinical target 1,40,41. This evidence concerns the gene FOXO1 and Insulin resistance.